DRF-1042 |
رقم الكتالوجGC38774 |
DRF-1042 هو مشتق فعال عن طريق الفم من كامبتوثيسينيعمل DRF-1042 على تثبيط DNA topoisomerase I. يُظهر DRF-1042 نشاطًا جيدًا مضادًا للسرطان ضد مجموعة من خطوط الخلايا السرطانية البشرية بما في ذلك النمط الظاهري لمقاومة الأدوية المتعددة (MDR)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 200619-13-2
Sample solution is provided at 25 µL, 10mM.
DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype[1][2].
DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype[2].
In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies[2].
[1]. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. [2]. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
Average Rating: 5
(Based on Reviews and 3 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *